SGLT2 inhibitors activate multiple anti-ageing mechanisms and demonstrably reduce cardiovascular and kidney disease, but whether they actually slow biological ageing in healthy people has not yet been proven in direct trials. The mechanistic and genetic evidence is promising but still insufficient to regard this as established fact.
SGLT2 inhibitors are diabetes medications (such as empagliflozin and dapagliflozin) that prompt the kidneys to excrete excess sugar through the urine. Several large clinical trials show that, in people both with and without diabetes, they significantly reduce the risk of heart failure, kidney failure, and all-cause mortality. That is the strongest and most direct evidence that these pills do more than simply lower blood sugar (PMID 33857309, 36293181, 37852518).
Researchers also found that SGLT2 inhibitors activate cellular processes that closely resemble what happens in the body during caloric restriction, a well-known way to slow ageing. Specifically, they activate energy sensors (AMPK and SIRT1) and suppress growth sensors (mTOR and the insulin/IGF1 pathway). This stimulates autophagy: the clean-up process by which cells break down and recycle damaged components. All these findings come largely from animal studies and laboratory experiments for now; sufficient direct evidence in humans is not yet available (PMID 33857309, 36293181, 37852518, 39796218).
Another ageing mechanism that SGLT2 inhibitors appear to suppress is 'inflammaging': the low-grade, chronic inflammation that increases with age and contributes to cardiovascular disease, dementia, and other age-related conditions. Both animal and human studies show that these drugs lower inflammatory markers, although those studies were not specifically designed as anti-ageing research and the precise magnitude of the effect has not been quantified (PMID 36293181, 33857309).
A Mendelian randomisation study, in which genetic variants are used as a proxy for lifelong SGLT2 inhibition, found an association with a longer lifespan (on average 6.2 additional years of life for the father per standard deviation reduction in HbA1c) and better cognition. A large part of the cognitive effect was mediated through changes in brain structure. This sounds impressive, but the method has serious limitations: it is not a direct measurement of people taking the medication, and genetic approaches carry their own uncertainties. The findings are interesting but far from proven (PMID 39270733).
In a very large Taiwanese study (more than 280,000 patients), SGLT2 inhibitors provided better kidney protection than GLP-1 agonists (another popular diabetes medication), including in frail older patients. The risk of dialysis or kidney transplantation was 2.4 to 3.9 times higher among GLP-1 users than among SGLT2 users, depending on how frail the patient was (PMID 39284334). Two notes of caution deserve attention. First, there is still no good research into how SGLT2 inhibitors interact with physical exercise, even though it is known that some anti-ageing compounds can counteract the health benefits of exercise when taken on the same day (PMID 38066609). Second, one review article suggests that dietary supplements could enhance the effects of SGLT2 inhibitors, but this evidence is weak and the authors have financial interests in supplement companies, which undermines objectivity (PMID 36522127).
The claims are based on large clinical trials (cardiovascular and kidney outcomes), one large observational study (Taiwan, n=280,000+), Mendelian randomisation, mechanistic/preclinical studies, and a review with a potential conflict of interest. No randomised trials have used lifespan or biological ageing as a primary endpoint. Meta-analyses were not provided as a direct source; however, large trials were included.